The impact potential of aflibercept biosimilars  

在线阅读下载全文

作  者:Adrienne Delaney Peter K.Kaiser 

机构地区:[1]Department of Ophthalmology,Cleveland Clinic Cole Eye Institute,Cleveland,OH,USA

出  处:《Annals of Eye Science》2025年第1期22-25,共4页眼科学年鉴(英文)

摘  要:A biologic drug is a medication produced from or containing components of living organisms.Given the rigorous testing that originator biologics undergo to establish Food and Drug Administration(FDA)Biologics License Application(BLA)approval,their subsequent price yields a high burden on healthcare systems(1).Biologics account for 37%of prescription drug spending,despite comprising only 2%of all prescribed medications(2).Biosimilar medicines are designed to have active properties that are“highly similar”to a previously licensed reference product,leading to increased chemistry,manufacturing,and controls(CMC).

关 键 词:BIOSIMILAR MYL-1701P BIOLOGIC ANTI-VEGF diabetic macular edema(DME) 

分 类 号:R95[医药卫生—药学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象